64 0

Full metadata record

DC FieldValueLanguage
dc.contributor.author이주연-
dc.date.accessioned2019-04-29T02:02:46Z-
dc.date.available2019-04-29T02:02:46Z-
dc.date.issued2016-10-
dc.identifier.citationCARDIOVASCULAR THERAPEUTICS, v. 34, No. 4, Page. 268-275en_US
dc.identifier.issn1755-5914-
dc.identifier.issn1755-5922-
dc.identifier.urihttps://onlinelibrary.wiley.com/doi/full/10.1111/1755-5922.12197-
dc.identifier.urihttps://repository.hanyang.ac.kr/handle/20.500.11754/102850-
dc.description.abstractAim Potential heterogeneity within the same class of drug in terms of persistence may lead to different clinical implications. Given that the increased risks of mortality and cardiovascular events are due, in part, to the lack of persistent use of antihypertensive medications, the objective of this study was to evaluate 1-year persistence of new-generation beta blockers compared to atenolol in antihypertensive treatment-naive patients. Methods A total of 9978 patients aged 18years or older with hypertension newly diagnosed in 2012, without hypertension-related complication and initiated treatment with beta blocker monotherapy during 2012 were included in the analysis. Rate and duration of treatment and drug persistence were compared between atenolol and new-generation beta blockers. Hazards of discontinuation in nonatenolol compared to atenolol were evaluated using a multivariate Cox proportional model. Results The rate of treatment persistence was higher in the nonatenolol group (57.35% vs 53.40%, P<.0001), and the time to treatment discontinuation was earlier in the atenolol group with a minimal difference in the average (243.2 vs 254days, P<.0001). New-generation beta blockers demonstrated a lower risk of treatment discontinuation (HR: 0.91, 95% CI: 0.86-0.96) compared to atenolol; a notable improvement was observed with carvedilol and nebivolol (HR: 0.74, 95% CI: 0.69-0.80 and HR: 0.79, 95% CI: 0.70-0.89, respectively), whereas betaxolol showed a substantially greater hazard for discontinuation compared to atenolol. Conclusions This study demonstrated a meaningful improvement in treatment persistence with new-generation beta blockers compared to atenolol, with betaxolol as exception.en_US
dc.description.sponsorshipThis work was supported by the Ministry of Health & Welfare (MOHW, Korea) [Project Name: A study on the improvement of drug safety for pharmaceutical care disparities in Korea]. However, design, analysis, data collection, and the interpretation of results were solely performed by each author listed.en_US
dc.language.isoen_USen_US
dc.publisherWILEY-BLACKWELLen_US
dc.subjectadherenceen_US
dc.subjectatenololen_US
dc.subjectbetaxololen_US
dc.subjectnew-generation beta blockeren_US
dc.subjectpersistenceen_US
dc.subjectRETROSPECTIVE CLAIMS ANALYSISen_US
dc.subjectMEDICATION ADHERENCEen_US
dc.subjectANTIHYPERTENSIVE THERAPYen_US
dc.subjectHYPERTENSIVE PATIENTSen_US
dc.subjectBLOOD-PRESSUREen_US
dc.subjectDRUG CLASSen_US
dc.subjectDISCONTINUATIONen_US
dc.subjectNEBIVOLOLen_US
dc.titleImplication of different initial beta blockers on treatment persistence: atenolol vs new-generation beta blocker, a population-based studyen_US
dc.typeArticleen_US
dc.relation.no4-
dc.relation.volume34-
dc.identifier.doi10.1111/1755-5922.12197-
dc.relation.page268-275-
dc.relation.journalCARDIOVASCULAR THERAPEUTICS-
dc.contributor.googleauthorChoi, Yun Jung-
dc.contributor.googleauthorAh, Young-Mi-
dc.contributor.googleauthorKong, Jisun-
dc.contributor.googleauthorChoi, Kyung Hee-
dc.contributor.googleauthorKim, Baegeum-
dc.contributor.googleauthorHan, Nayoung-
dc.contributor.googleauthorYu, Yun Mi-
dc.contributor.googleauthorOh, Jung Mi-
dc.contributor.googleauthorShin, Wan Gyoon-
dc.contributor.googleauthorLee, Ju-Yeun-
dc.contributor.googleauthorLee, Hae-Young-
dc.relation.code2016001209-
dc.sector.campusE-
dc.sector.daehakCOLLEGE OF PHARMACY[E]-
dc.sector.departmentDEPARTMENT OF PHARMACY-
dc.identifier.pidjypharm-
Appears in Collections:
COLLEGE OF PHARMACY[E](약학대학) > PHARMACY(약학과) > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE